ArticleScientific reports2019
Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Benefit of adjuvant radiotherapy for gallbladder cancer: a comparability-based meta-analysis.Hepatology international · 2022Pooled it
- Pooled it
- Long-term Outcomes in Gallbladder Cancer Patients Treated with Curative-Intent Resection: Adjuvant Chemotherapy Versus Observation in a Multicenter Propensity Score-Matched Study.Annals of surgical oncology · 2026Article
- Optimizing Lymph Node Staging in Gallbladder Cancer: A Cutoff of 11 Nodes for Accurate Staging and Improved Survival.Journal of hepato-biliary-pancreatic sciences · 2026Article
- Challenges and innovations in adjuvant therapy for gallbladder cancer: a meta-analytic perspective.Hepatobiliary surgery and nutrition · 2026Article
- Impact of adjuvant therapy on survival outcomes in resected gallbladder cancer: a systematic review and meta-analysis.Hepatobiliary surgery and nutrition · 2026Article
- Role of Radiation Therapy for Biliary Tract Cancers.Current oncology (Toronto, Ont.) · 2025Review
- Effects of radiotherapy, chemotherapy, and chemoradiotherapy on survival outcomes in patients with gallbladder carcinoma: a real population-based study.Translational cancer research · 2025Article
- Survival after extended resections for gallbladder cancer.Annals of hepato-biliary-pancreatic surgery · 2023Article
- Gallbladder Cancer: A Single-Institution 10-Year Experience-Analysis of Adenocarcinoma Subtypes and Tumors Arising from Intracholecystic Papillary Neoplasms.Annals of surgical oncology · 2022Article
- Comment on: development and external validation of a model to predict overall survival in patients with resected gallbladder cancer.Hepatobiliary surgery and nutrition · 2022Article
- Extended Resections for Advanced Gallbladder Cancer: Results from a Nationwide Cohort Study.Annals of surgical oncology · 2021Article
- Article
- Prognostic impact of lymphovascular invasion in pT1-T3 gallbladder adenocarcinoma.Journal of surgical oncology · 2020Article
- Observational
- The Efficacy of Adjuvant Chemoradiotherapy in Early-Stage Gallbladder Adenocarcinoma Depends on the Tumor Invasion Depth and Differentiation Level.Frontiers in oncology · 2020Article
- Expression of Formin-like 2 and cortactin in gallbladder adenocarcinoma and their clinical significance.International journal of clinical and experimental pathology · 2020Article
- Role of Adjuvant Treatment in High-risk Patients Following Resection for Gallbladder Cancer.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the benefit of adjuvant treatments, such as chemoradiotherapy (CRT) and chemotherapy (CTx), compared with no adjuvant treatment (No-AT) in resected gallbladder (GB) cancer patients, 151 patients were analyzed: 98 (64.9%) patients received adjuvant treatment with CRT (n = 59, 39.1%) or CTx (n = 39, 25.8%), and the remaining 53 (35.1%) did not (No-AT). The clinicopathological factors, patterns of failure, locoregional recurrence-free survival (LRFS), recurrence-free survival (RFS) and overall survival (OS) were compared among the three groups according to tumor stage. In patients with T2-3N0M0 stage disease, the incidences of locoregional recurrence and distant recurrence and 5-year LRFS, RFS and OS rates were not significantly different among the No-AT, CTx, and CRT groups (p > 0.05 each). In those with T2-3N1-2M0 stage disease, the incidences of locoregional recurrence (11.4%, 78.1%, and 68.4%, respectively) and distant recurrence (42.8%, 73.9% and 66.7%, respectively) in the CRT group were significantly lower than those in the No-AT and CTx groups (p < 0.05), and the CRT group had significantly higher 5-year LRFS (82,1%, 26.8%, and 19.0%), RFS (53.3%, 11.6% and 16.7%) and OS rates (64.0%, 22.7% and 4.3%) than the CTx and No-AT groups (p < 0.05 each). Therefore, adjuvant CRT may improve the LRFS and RFS and subsequently improve OS in lymph node-positive resected GB cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.